Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05943327 · ClinicalTrials.gov registry record · Phase 1
A Study Investigating Lu AG06474 in Healthy Young Participants
A Phase 1 study, sponsored by H. Lundbeck A/S.
- Terminated
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT05943327 is a Phase 1 study that was terminated before completion, run by H. Lundbeck A/S. The registered enrollment target is 56 participants.
The verdict
NCT05943327, a Phase 1 study, was terminated before completion, sponsored by H. Lundbeck A/S.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the safety of multiple oral doses of Lu AG06474, how well the doses are tolerated, and what the body does to the drug after administering it to healthy young participants. This study also aims to compare how the body absorbs and uses Lu AG06474 when it is given in capsule form versus when it is given as an oral solution.
Interventions
- DRUG Placebo
- DRUG Lu AG06474
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2023-06-28 |
| Est. Completion | 2024-07-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05943327
The ClinicalTrials.gov registry entry for NCT05943327 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05943327 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05943327 about?
NCT05943327 is a clinical study titled "A Study Investigating Lu AG06474 in Healthy Young Participants". The purpose of this study is to investigate the safety of multiple oral doses of Lu AG06474, how well the doses are tolerated, and what the body does to the drug after administering it to healthy young participants. This study also aims to compare how the body absorbs and uses Lu AG06474 when it is ...
What is the current status of trial NCT05943327?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2023-06-28. Estimated completion is 2024-07-19.
What interventions are being tested in trial NCT05943327?
The interventions under investigation include: Placebo (DRUG), Lu AG06474 (DRUG).
Who is sponsoring clinical trial NCT05943327?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.